Related Experiment Videos
Routine pulmonary function tests during bleomycin therapy. Tests may be ineffective and potentially misleading.
JAMA
|January 25, 1980
Summary
Pulmonary function tests like forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLco) may be unreliable for detecting bleomycin toxicity. These tests can yield misleading results due to factors like weakness and anemia.
Area of Science:
- Pulmonary Medicine
- Toxicology
- Oncology
Background:
- Bleomycin is a chemotherapy agent used to treat various cancers.
- Interstitial fibrosis is a serious potential side effect of bleomycin treatment.
- Pulmonary function tests are used to monitor lung health during chemotherapy.
Purpose of the Study:
- To evaluate the effectiveness of forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLco) in detecting bleomycin-induced lung toxicity.
- To compare test results in patients with and without interstitial fibrosis after bleomycin treatment.
Main Methods:
- Retrospective analysis of FVC and DLco data.
- Comparison of pulmonary function test results between patients who developed interstitial fibrosis and those who did not.
- Inclusion of correction for hemoglobin levels to assess DLco accuracy.
Main Results:
- FVC decreased significantly in patients with fibrosis and in some without.
- DLco decreased in patients with fibrosis and in others.
- Hemoglobin correction did not fully account for DLco changes and sometimes altered significance.
Conclusions:
- FVC and DLco tests may produce false-positive and false-negative results for bleomycin lung toxicity.
- Factors such as patient weakness and anemia can significantly impact test interpretation.
- The clinical utility of FVC and DLco for monitoring bleomycin lung toxicity is questionable due to potential inaccuracies.